Literature DB >> 1731223

A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension.

R P Lifton1, R G Dluhy, M Powers, G M Rich, S Cook, S Ulick, J M Lalouel.   

Abstract

Glucocorticoid-remediable aldosteronism (GRA), an autosomal dominant disorder, is characterized by hypertension with variable hyperaldosteronism and by high levels of the abnormal adrenal steroids 18-oxocortisol and 18-hydroxycortisol, which are all under control of adrenocorticotropic hormone and suppressible by glucocorticoids. These abnormalities could result from ectopic expression of aldosterone synthase, which is normally expressed only in adrenal glomerulosa, in the adrenal fasciculata. Genes encoding aldosterone synthase and steroid 11 beta-hydroxylase (expressed in both adrenal fasciculata and glomerulosa), which are 95% identical and lie on chromosome 8q (refs 7, 10), are therefore candidate genes for GRA. Here we demonstrate complete linkage of GRA in a large kindred to a gene duplication arising from unequal crossing over, fusing the 5' regulatory region of 11 beta-hydroxylase to the coding sequences of aldosterone synthase (maximum lod score 5.23 for complete linkage, odds ratio of 170,000:1). This mutation can account for all the physiological abnormalities of GRA. Our result represents the demonstration of a mutation causing hypertension in otherwise phenotypically normal animals or humans.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1731223     DOI: 10.1038/355262a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  198 in total

Review 1.  Investigation of hypertension and the recognition of monogenic hypertension.

Authors:  D V Milford
Journal:  Arch Dis Child       Date:  1999-11       Impact factor: 3.791

2.  Measurement and interpretation of blood pressure.

Authors:  C D Goonasekera; M J Dillon
Journal:  Arch Dis Child       Date:  2000-03       Impact factor: 3.791

Review 3.  Matching the right drug to the right patient in essential hypertension.

Authors:  M J Brown
Journal:  Heart       Date:  2001-07       Impact factor: 5.994

Review 4.  Hyperaldosteronism: recent concepts, diagnosis, and management.

Authors:  R Foo; K M O'Shaughnessy; M J Brown
Journal:  Postgrad Med J       Date:  2001-10       Impact factor: 2.401

5.  Contemporary management of refractory hypertension.

Authors:  A B Alper; D A Calhoun
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

Review 6.  Epidemiology of risk factors for hypertension: implications for prevention and therapy.

Authors:  M Kornitzer; M Dramaix; G De Backer
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 7.  Primary aldosteronism: rare bird or common cause of secondary hypertension?

Authors:  M Stowasser
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

Review 8.  Primary aldosteronism.

Authors:  R D Gordon
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

Review 9.  Between candidate genes and whole genomes: time for alternative approaches in blood pressure genetics.

Authors:  Jacob Basson; Jeannette Simino; D C Rao
Journal:  Curr Hypertens Rep       Date:  2012-02       Impact factor: 5.369

Review 10.  Genetic rat models of hypertension: relationship to human hypertension.

Authors:  M Stoll; H J Jacob
Journal:  Curr Hypertens Rep       Date:  2001-04       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.